LLTP News 0.0356 Lightlake Therapeutics (LLTP)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lightlake Therapeutics (LLTP) 0.0356 $LLTP

Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
PR Newswire - Fri Dec 20, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013.

Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
PR Newswire - Tue Dec 03, 3:05PM CST
Lightlake Therapeutics Inc. ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, has announced that the initial findings of its clinical trial with the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health, supports Lightlake's intranasal delivery of naloxone as a promising innovative treatment for opioid overdose.

Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid

Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
PR Newswire - Wed Nov 20, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it is scheduled to present at LD MICRO's 6th Annual Conference on Wednesday, December 4th, 2013, at 8:30 AM PST / 11:30 AM EST. The three-day event will host more than 200 companies in the micro-cap space at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

OTC Signal Daily Stock Watch - Lightlake Therapeutics Inc., (OTCQB: LLTP)
WorldStockWire - Tue Sep 03, 8:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Lightlake Therapeutics Announces Partnership with National Institute on Drug Abuse (NIDA) to Treat Opioid Overdose
PR Newswire - Wed Aug 21, 7:30AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today the Company is moving forward in expanding access to medication for the treatment of opioid overdose with the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" . This fall, NIDA will sponsor a two-week clinical study designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
PR Newswire - Mon Aug 05, 8:00AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA" , a leading New York-based communications firm, to direct the Company's investor and public relations programs.

Lightlake Therapeutics Inc. to Present at 4th Annual OneMedForumNY 2013
Business Wire - Tue Jun 18, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be participating in the 4th Annual OneMedForum New York taking place June 26th and June 27th, 2013 at The Metropolitan Club in New York City. Dr. Roger Crystal, Chief Executive Officer of Lightlake, is scheduled to present an update on the Company's corporate and clinical developments on Thursday, June 27th at 12:20 p.m. EDT.

Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
Business Wire - Thu May 23, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder ("BED" were presented at the American Psychiatric Association ("APA" Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

Lightlake Therapeutics Inc. to Develop Opioid Drug Treatment in Collaboration with the National Institute on Drug Abuse (NIDA)
Business Wire - Wed Apr 24, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse ("DPMCDA" of the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to co-develop a treatment for opioid addiction that utilizes the Company's innovative proprietary technology.

Lightlake Therapeutics Inc. Provides Guidance on Company Operations
Business Wire - Thu Apr 04, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , an early stage biopharmaceutical company developing addiction treatments, announced today the clinical progress and corporate developments the Company has achieved during the last six months, and provided insights on its plans to develop opioid drug addiction treatments.

Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
Business Wire - Wed Mar 27, 5:30AM CDT
Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the "Company" or "Lightlake" , an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

Addiction - Pipeline Review: Latest updates and review of key players
M2 - Wed Jan 09, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2xs3/addiction) has announced the addition of Global Markets Direct's new report "Addiction - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Addiction. - A review of the Addiction products under development by companies and universities/research institutes based on information derived from com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 17

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 85

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 57

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 76

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 41

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 16

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 70

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 9

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 111

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading

Top 5 Most Recently Viewed Articles

Gamehaus Holdings Inc. Launches Strategic Share Buyback Plan

Updated Category News Views 222

Gamehaus Holdings Inc. Introduces New Share Repurchase Program Gamehaus Holdings Inc. (Nasdaq: GMHS), a leading mobile game publisher focused on technology, has announced a significant move aimed at returning value to its shareholders. The company has authorized a share repurchase program that allows it to buy back up to US$5 million of its Class A ordinary shares. This...

Continue Reading
AMN Healthcare's Upcoming Earnings Call: What to Expect

Updated Category News Views 191

AMN Healthcare's Upcoming Earnings Conference Call AMN Healthcare Services, Inc. (NYSE: AMN) has announced an important conference call planned for Thursday, November 6, 2025, at 5:00 p.m. Eastern Time. This event aims to provide valuable insights into the company’s third quarter financial results and the outlook for the fourth quarter of the same year. Investors and...

Continue Reading
J&T Express Marks Profit Milestone in 2024 with Strong Growth

Updated Category News Views 520

J&T Express Achieves Profit Milestone Amid Impressive Growth J&T Global Express Limited, commonly known as J&T Express, reported remarkable achievements in its recent annual results, highlighting significant milestones in revenue growth and profitability. In a remarkable development, the company made a substantial leap in the logistics sector, marking its first full-year...

Continue Reading
Innovative Smart Walking Stick Enhances Safety for Users

Updated Category News Views 207

Introducing the Artisan Smart Walking Stick In a world where mobility and safety are paramount, innovation plays a crucial role in enhancing the lives of individuals. The Artisan Smart Walking Stick is a groundbreaking invention emerging from dedicated inventors focused on providing greater independence and safety for users like the elderly and visually impaired. The...

Continue Reading
Golden Ocean Group Limited Announces AGM Resolutions and Results

Updated Category News Views 156

Golden Ocean Group Limited 2025 Annual General Meeting Overview Golden Ocean Group Limited, known by the ticker symbols Oslo:GOGL and Nasdaq:GOGL, recently held its Annual General Meeting (AGM), an essential gathering designed to keep shareholders informed and involved in the company's progress and direction. The meeting showcased the financial health of the organization,...

Continue Reading